In December 2019, a cluster of patients presented with emerging viral pneumonia in Wuhan, China, and were found to be infected with a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) \[[@CIT0001]\]. As of 20 March 2020, SARS-CoV-2 has led to 326 558 confirmed cases worldwide, including 14 267 deaths. The clinical spectrums of confirmed SARS-CoV-2 infection appears to be variable, ranging from asymptomatic infection, mild upper respiratory tract illness, moderate lung infection with radiological abnormalities, to severe viral pneumonia with respiratory failure and in some cases death \[[@CIT0004]\]. Epidemiological and clinical characteristics of patients with coronavirus disease 2019 (COVID-19) have been reported but the pathogenesis of SARS-CoV-2 infection has not been well defined \[[@CIT0007], [@CIT0008]\].

Virus-induced aberrant and excessive cytokine production (also known as hypercytokinemia) has been linked to morbidity and mortality in several viral infections \[[@CIT0009]\]. Also, it has been reported that hyperinduction of proinflammatory cytokine plays an important role in the disease progression and the ultimate death of patients infected with SARS-CoV \[[@CIT0014], [@CIT0015]\], Middle East respiratory syndrome coronavirus (MERS-CoV) \[[@CIT0012]\], and SARS-CoV-2 \[[@CIT0008], [@CIT0016]\] infection. However, the cytokine and chemokine profiles in SARS-CoV-2--infected cases with different degrees of disease severity remain unclear. In the present study, we investigated the serum cytokine and chemokine levels in asymptomatic, and mild, moderate, severe, and convalescent SARS-CoV-2--infected cases in Jiangsu Province, China. Furthermore, the relationships between sex and viral load and the levels of serum cytokines and chemokines in SARS-CoV-2--infected patients were explored. The findings of this research will further our understanding of the immunoregulatory events in disease progression and the pathogenesis of SARS-CoV-2 infection.

METHODS {#s1}
=======

Population and Samples {#s2}
----------------------

A total of 70 SARS-CoV-2--infected patients, diagnosed by real-time reverse transcription polymerase chain reaction (RT-PCR) or next-generation sequencing, and 4 convalescent cases in Jiangsu Province, China were included in this study. Of the 70 patients, 4 were asymptomatic and 66 were symptomatic. Serum samples of symptomatic cases were collected 1 to approximately 11 days after disease onset. According to the "Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance" (version 5) published by the National Health Commission of China \[[@CIT0017]\], the 66 symptomatic cases can be categorized into different clinical groups. The 22 mild cases had slight clinical symptoms and no radiological changes, the 36 moderate cases had fever, respiratory tract symptoms, and radiological abnormalities, and the 8 severe cases (including 1 critical cases) had at least 1 of the following: (1) respiratory distress with respiration rate ≥ 30 times/min, (2) oxygen saturation at rest ≤ 93%, (3) arterial Pa[o]{.smallcaps}~2~/Fi[o]{.smallcaps}~2~ ≤ 300 mmHg, and (4) respiratory failure, shock, or other organ failure requiring intensive care unit treatment. Additionally, 4 convalescent cases and 4 age- and sex-matched healthy controls who had undergone routine physical examinations in Jiangsu Province were also included. The exclusion criteria for healthy control individuals were as follows: acute or chronic infectious disease, any clinically significant disorder, and any medication with known influence on immunological factors. All procedures conducted in this study involving human materials were approved by the Jiangsu Provincial Center for Disease Control Ethics Committee.

Cytokine and Chemokine Assay {#s3}
----------------------------

A total of 48 serum cytokines and chemokines were measured in a multiplex biometric immunoassay containing fluorescent microspheres conjugated with target-specific monoclonal antibodies according to the manufacturer's instructions (Bio-Plex Pro Human Cytokine Screening 48-plex panel; Bio-Rad) and were detected on the Luminex 200 system (Luminex). According to their functions, the cytokines/chemokines were grouped into 6 categories: interleukins (IL-1α, IL-1β, IL-1ra, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-16, IL-17, and IL-18), colony stimulating factors (G-CSF, GM-CSF, M-CSF, and stem cell factor \[SCF\]), interferons (IFN-α2 and IFN-γ), tumor necrosis factor (TNF-α, TNF-β, and TNF-related apoptosis inducing ligand \[TRAIL\]), growth factors (basic fibroblast growth factor \[FGF\], nerve growth factor-β \[NGF-β\], hepatocyte growth factor \[HGF\], leukemia inhibitory factor \[LIF\], platelet-derived growth factor \[PDGF-BB\], vascular endothelial growth factor \[VEGF\], and stem cell growth factor-β \[SCGF-β\]), and chemokine family (cutaneous T-cell-attracting chemokine \[CTACK\], eotaxin, growth related oncogene-α \[GRO-α\], IFN-γ inducible protein-10 \[IP-10\], monocyte chemoattractant protein-1 \[MCP-1\], MCP-3, migration inhibitory factor \[MIF\], monokine induced by interferon-γ \[MIG\], macrophage-inflammatory protein \[MIP-1α\], MIP-1β, regulated upon activation normal T-cell expressed and secreted \[RANTES\], and stromal cell-derived factor-1α \[SDF-1α\]).

SARS-CoV-2 Viral Load Detection {#s4}
-------------------------------

The SARS-CoV-2 viral loads of respiratory specimens were detected by real-time RT-PCR. The viral N gene was detected with a commercial kit according to the manufacturer's instructions (SARS-CoV-2 Nucleic Acid test kit; BioGem). Human ribonucleases P (Rnasep) was selected as the internal reference gene. The relative viral load of each patient was calculated by using the equation 2^−△Ct^, in which △ cycle threshold value (Ct) = Ct~viral\ N\ gene~−Ct ~RnaseP~. Data was translated to log~2~ (relative viral load), which was equivalent to −△Ct values \[[@CIT0018]\].

Statistical Analysis {#s5}
--------------------

All statistical analyses were performed with SPSS (version 20.0), and the figures were prepared using GraphPad Prism (version 8.0). Normally distributed quantitative data is presented as mean ± standard deviation (SD), while nonnormally distributed data is presented as median (25th--75th percentile). The nonparamentic Mann-Whitney *U* test was used to compare the levels of serum cytokines between 2 groups. To explore the correlations between cytokines and the viral load, Spearman correlation analyses were performed because the distributions of variables were not normal; heat map analyses of the correlation coefficients were then conducted. The results were considered statistically significant if the *P* values were \< .05.

RESULTS {#s6}
=======

**Serum Cytokine and Chemokine Levels in SARS-CoV-2**--**Infected Asymptomatic, Symptomatic, and Convalescent Cases** {#s7}
---------------------------------------------------------------------------------------------------------------------

We first investigated the serum cytokine and chemokine levels in asymptomatic, symptomatic, and convalescent cases and healthy controls. Compared with healthy controls, the serum IL-7, IL-10, and IP-10 levels were significantly higher in asymptomatic cases. The serum IL-1β, IL-1ra, IL-2, IL-2Rα, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-15, IL-17, IL-18, G-CSF, M-CSF, IFN-α2, IFN-γ, TNF-α, TRAIL, basic FGF, HGF, PDGF-BB, VEGF, GRO-α, IP-10, MCP-1, and MIG levels were higher in symptomatic patients ([Table 1](#T1){ref-type="table"}). The eotaxin level was lower in symptomatic cases than healthy controls. Further comparison between asymptomatic and symptomatic cases showed that serum concentrations of IL-1ra, IL-1β, IL-6, and IP-10 were lower in asymptomatic cases than symptomatic cases. As expected, all of the cytokine and chemokine levels in convalescent cases were similar to asymptomatic cases and healthy controls. However, the serum levels of IL-1β, IL-1ra, IL-2, IL-6, IL-8, IL-9, IL-10, IL-12 (p40), IL-13, IL-15, IL-18, G-CSF, M-CSF, IFN-α2, IFN-γ, TNF-α, TRAIL, basic FGF, NGF-β, VEGF, CTACK, GRO-α, IP-10, MCP-1, MCP-3, MIF, and MIG in convalescent cases were significantly lower than those in symptomatic cases. Moreover, there were no statistically significant differences in the serum levels of IL-1α, IL-3, IL-4, IL-5, IL-12(p70), IL-16, GM-CSF, SCF, TNF-β, LIF, SCGF-β, MIP-1α, MIP-1β, RANTES, and SDF-1α between any of the groups, as shown in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics and Serum Cytokine and Chemokine Levels of SARS-CoV-2--Infected Asymptomatic, Symptomatic, and Convalescent Cases and Healthy Controls (n = 78)

  Characteristic                                           Control (n = 4)                       Asymptomatic (n = 4)                  Symptomatic (n = 66)                  Convalescent (n = 4)
  -------------------------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------
   Age, y, mean ± SD                                       47.75 ± 7.85                          42.00 ± 10.98                         43.24 ± 14.76                         40.25 ± 16.09
   Men, No. (%)                                            2 (50)                                1 (25)                                37 (56)                               2 (50)
   Women, No. (%)                                          2 (50)                                3 (75)                                29 (44)                               2 (50)
   Time, d, mean ± SD                                                                                                                  4.41 ± 3.47                           35.75 ± 5.68
   No. of deaths                                           0                                     0                                     0                                     0
  Serum cytokines, pg/mL, median (25th--75th percentile)                                                                                                                     
   IL-1α                                                   22.30 (10.83--30.47)                  24.19 (17.74--66.16)                  18.73 (14.14--26.15)                  18.00 (11.19--20.21)
   IL-1β                                                   4.73 (4.06--5.61)                     6.78 (4.69--13.33)                    13.07 (8.55--21.97)^b,d^              4.47 (2.82--6.49)^e^
   IL-1ra                                                  389.80 (341.40--489.50)               512.40 (298.60--1159.00)              1441.00 (771.40--2255.00)^b,d^        405.40 (156.40--1022.00)^c^
   IL-2                                                    3.93 (2.77--5.48)                     7.46 (2.48--13.02)                    9.69 (5.09--15.22)^a^                 2.99 (1.00--3.59)^c^
   IL -2Rα                                                 97.08 (65.54--103.80)                 113.00 (68.77--184.20)                189.68 (150.76--224.33)^d^            99.33 (47.09--186.00)
   IL -3                                                   0.77 (0.40--1.26)                     0.61 (0.47--1.72)                     0.68 (0.32--1.01)                     0.61 (0.32--0.83)
   IL -4                                                   8.81 (8.42--10.58)                    8.11 (5.34--10.19)                    9.31 (7.48--11.01)                    7.46 (5.83--9.16)
   IL -5                                                   12.69 (5.38--21.80)                   11.48 (6.12--16.65)                   15.15 (8.62--78.05)                   10.60 (6.31--40.54)
   IL -6                                                   6.53 (5.17--10.47)                    6.44 (2.34--13.94)                    15.30(7.70--22.64)^a,b^               2.51 (1.18--4.86)^e^
   IL -7                                                   14.39 (12.04--17.56)                  29.15 (21.26--33.79)^a^               28.84 (22.41--35.30)^d^               22.69 (13.56--27.58)
   IL -8                                                   11.28 (8.88--14.65)                   17.79 (12.18--33.72)                  33.29 (17.58--44.74)^a^               4.18 (2.88--9.78)^e^
   IL -9                                                   259.70 (234.60--323.00)               351.80 (334.60--375.10)               391.77 (339.97--422.54)^d^            274.80 (266.60--340.80)^e^
   IL -10                                                  2.57 (2.10--3.60)                     7.80 (6.42--8.17)^a^                  9.60 (5.64--13.24)^a^                 2.37 (0.83--5.53)^c^
   IL -12 (p40)                                            160.50 (146.20--181.50)               246.10 (131.70--374.60)               246.10 (138.20--333.10)               56.29 (22.43--140.60)^c^
   IL -12 (p70)                                            6.11 (4.05--8.33)                     8.06 (4.22--13.62)                    6.68 (6.05--9.80)                     5.16 (3.18--6.06)
   IL -13                                                  6.24 (3.88--13.24)                    6.23 (2.73--21.15)                    19.95 (8.91--50.67)^a^                4.71 (2.30--7.55)^e^
   IL -15                                                  337.80 (315.80--408.80)               353.00 (166.00--575.90)               560.25 (452.68--700.58)^d^            243.50 (157.20--317.00)^e^
   IL -16                                                  130.80 (119.30--142.70)               84.79 (50.40--170.60)                 135.50 (100.30--178.80)               90.59 (57.76--127.90)
   IL -17                                                  11.35 (8.51--13.54)                   21.17 (11.90--24.68)                  16.63 (13.38--20.54)^a^               15.17 (10.48--19.84)
   IL -18                                                  76.37 (66.95--94.23)                  75.93 (26.14--141.10)                 129.94 (99.26--165.04)^a^             79.55 (46.63--109.80)^c^
   G-CSF                                                   83.54 (70.97--98.15)                  78.14 (24.90--176.00)                 153.56 (117.73--243.29)^a^            69.94 (48.21--103.50)^c^
   GM-CSF                                                  9.54 (4.23--13.75)                    5.49 (0.91--16.48)                    7.83 (5.69--14.92)                    8.02 (7.08--11.51)
   M-CSF                                                   23.68 (21.07--27.11)                  26.18 (13.88--49.79)                  47.82 (31.91--64.80)^d^               17.51 (12.60--32.65)^e^
   SCF                                                     129.60 (114.80--136.50)               91.15 (48.13--184.40)                 121.70 (86.10--157.80)                72.65 (59.76--134.10)
   IFN-α2                                                  19.67 (15.17--21.19)                  19.37 (15.77--29.36)                  28.21 (22.97--36.17)^d^               16.45 (13.02--21.90)^e^
   IFN-γ                                                   33.91 (27.84--40.03)                  48.21 (27.81--73.78)                  57.96 (44.02--72.15)^d^               34.17 (27.54--42.97)^c^
   TNF-α                                                   129.50 (98.75--151.60)                151.50 (141.20--191.30)               185.40 (164.80--213.70)^d^            127.70 (102.60--152.30)^e^
   TNF-β                                                   483.70 (423.30--554.80)               515.70 (487.20--533.10)               498.50 (444.10--559.50)               427.70 (399.10--487.40)
   TRAIL                                                   101.80 (94.15--105.90)                107.80 (102.70--183.50)               160.60 (129.20--204.50)^d^            94.34 (83.14--102.10)^e^
   Basic FGF                                               63.94 (61.88--73.58)                  80.50 (53.65--106.00)                 90.24 (76.07--99.97)^d^               59.38 (52.36--66.95)^e^
   NGF-β                                                   4.47 (3.66--5.80)                     3.53 (1.47--6.98)                     5.58 (4.26--7.26)                     2.39 (0.14--5.14)^c^
   HGF                                                     451.90 (378.20--667.40)               562.00 (460.30--904.00)               801.20 (601.80--1034.00)^a^           597.70 (363.50--719.10)
   LIF                                                     113.90 (66.46--168.70)                95.43 (59.16--181.20)                 155.10 (96.78--222.70)                67.37 (32.76--150.60)
   PDGF-BB                                                 1179.00 (802.40--1834.00)             2478.00 (1582.00--3309.00)            2159.00 (1745.00--3068.00)^a^         1524.00 (695.60--2034.00)
   VEGF                                                    325.90 (254.00--474.90)               517.00 (120.80--776.40)               766.24 (597.48--1012.05)^d^           356.60 (118.60--576.80)^c^
   SCGF-β                                                  154 524.00 (143 555.00--161 369.00)   174 667.00 (138 947.00--243 362.00)   184 009.00 (157 334.00--223 500.00)   149 084.00 (117 874.00--164 752.00)
   CTACK                                                   925.60 (841.50--1007.00)              958.70 (688.50--1517.00)              1060.00 (822.40--1551.00)             581.60 (367.50--838.60)^e^
   Eotaxin                                                 36.21 (26.47--53.73)                  35.14 (16.24--59.31)                  15.45(11.61--25.51)^a^                29.28 (18.62--52.00)
   GRO-α                                                   1001.00 (979.30--1067.00)             1129.00 (963.40--1286.00)             1326.00 (1190.00--1439.00)^a^         832.30 (796.40--1026.00)^e^
   IP-10                                                   110.30 (103.00--131.20)               594.40 (397.00--846.20) ^a^           1655.00 (833.20--2458.00)^d,b^        279.90 (144.20--369.50)^e^
   MCP-1                                                   72.61 (49.26--86.25)                  68.16 (42.12--182.80)                 128.70 (86.21--197.40)^a^             41.75 (19.27--51.44)^e^
   MCP-3                                                   3.79 (3.01--5.09)                     2.20 (1.04--7.97)                     3.89 (2.30--5.69)                     1.07 (0.26--3.71)^c^
   MIP-1α                                                  2.82 (1.94--3.16)                     3.01 (2.33--5.39)                     3.12 (2.69--4.00)                     2.81 (2.00--3.08)
   MIP-1β                                                  319.90 (293.80--346.00)               347.30 (299.40--430.70)               330.00 (292.60--367.50)               291.40 (273.10--327.90)
   MIF                                                     2118.00 (1917.00--2705.00)            2572.00 (681.10--5435.00)             3318.00 (1963.00--5421.00)            1228.00 (652.40--1895.00)^c^
   MIG                                                     131.00 (97.84--181.00)                178.90 (157.30--266.60)               233.40 (161.10--354.40)^a^            150.60 (96.84--185.10)^c^
   RANTES                                                  9057.00 (8137.00--12 137.00)          10 361.00 (5512.00--22 377.00)        7409.00 (4362.00--12 982.00)          7776.00 (3468.00--8775.00)
   SDF-1α                                                  484.90 (331.10--707.50)               469.40 (320.90--920.00)               338.90 (260.10--436.00)               469.80 (251.30--628.20)

Abbreviations: CSF, colony-stimulating factor; CTACK, cutaneous T cell-attracting chemokine; FGF, fibroblast growth factor; GRO-α, growth related oncogene-α; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; IP-10, IFN-γ inducible protein-10; LIF, leukemia inhibitory factor MCP, monocyte chemoattractant protein; MIF, migration inhibitory factor; MIG, monokine induced by interferon-γ; MIP, macrophage-inflammatory protein; NGF-β, nerve growth factor-β; PDGF, platelet-derived growth factor; RANTES, regulated upon activation normal T-cell expressed and secreted; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCF, stem cell factor; SCGF-β, stem cell growth factor-β; SDF-1α, stromal cell-derived factor-1α; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis inducing ligand; VEGF, vascular endothelial growth factor.

^a^ *P*\< .05 verses control.

^b^ *P*\< .05 verses asymptomatic.

^c^ *P*\< .05 verses symptomatic.

^d^ *P*\< .01 verses control.

^e^ *P*\< .01 verses symptomatic.

Serum Cytokine and Chemokine Levels in SARS-CoV-2--Infected Patients With Mild, Moderate, and Severe Disease {#s8}
------------------------------------------------------------------------------------------------------------

We further examined these cytokine and chemokine levels in symptomatic patients with different degrees of disease severity. The demographic and clinical characteristics of patients with different disease severity and healthy controls are shown in [Table 2](#T2){ref-type="table"}. There were no statistically significant differences in the serum levels of IL-1α, IL-3, IL-4, IL-5, IL-12(p40), IL-12(p70), IL-16, GM-CSF, SCF, TNF-β, basic FGF, LIF, SCGF-β, CTACK, MIP-1β, MIF, RANTES, and SDF-1α among overall groups. Compared with the healthy individuals, the mild cases had higher levels of serum IL-1β, IL-1ra, IL-2Rα, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-15, IL-17, M-CSF, IFN-α2, IFN-γ, TNF-α, TRAIL, basic FGF, HGF, PDGF-BB, VEGF, eotaxin, GRO-α, IP-10, and MIG; the moderate cases had higher levels of serum IL-1β, IL-1ra, IL-2Rα, IL-6, IL-7, IL-8, IL-9, IL-10, IL-15, IL-18, G-CSF, M-CSF, IFN-α2, IFN-γ, TNF-α, TRAIL, basic FGF, HGF, PDGF-BB, VEGF, eotaxin, GRO-α, IP-10, and MIG; and the severe cases had higher levels of serum IL-1β, IL-1ra, IL-2, IL-2Rα, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-17, IL-18, G-CSF, M-CSF, IFN-α2, IFN-γ, TNF-α, TRAIL, HGF, PDGF-BB, VEGF, eotaxin, IP-10, MCP-1, MCP-3, MIG, and MIP-1α. Compared with the mild cases, the severe cases had higher serum concentrations of IL-6, IL-7, IL-10, G-CSF, M-CSF, IP-10, MCP-1, MCP-3, MIG, and MIP-1α; and the moderate cases had higher serum concentrations of IL-18, IP-10, and M-CSF. Moreover, the severe cases also had higher levels of MCP-3, MIG, and MIP-1α than the moderate cases ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table 1](#sup2){ref-type="supplementary-material"}).

###### 

Demographic and Clinical Characteristics of SARS-CoV-2--Infected Symptomatic Patients With Mild, Moderate, and Severe Disease

  Characteristics                  Control (n = 4)   Mild (n = 22)   Moderate (n = 36)   Severe (n = 8)
  -------------------------------- ----------------- --------------- ------------------- ----------------
  Age, y, mean ± SD                47.75 ± 7.85      43.32 ± 18.38   40.81 ± 11.80       54.00 ± 12.38
  Men                              2 (50)            13 (59)         19 (53)             5 (63)
  Women                            2 (50)            9 (41)          17 (47)             3 (37)
  Time from onset, d, mean ± SD    NA                4.45 ± 4.76     4.42 ± 2.81         4.25 ± 2.05
  No. of deaths                    0                 0               0                   0
  Fever (temperature ≥ 37.3℃)      0                 16 (73)         33 (92)             8 (100)
  Malaise                          0                 6 (27)          13 (36)             2 (25)
  Cough                            0                 7 (32)          15 (42)             2 (25)
  Sputum                           0                 5 (23)          9 (25)              3 (38)
  Pharyngalgia                     0                 3 (14)          10 (28)             1 (13)
  Headache                         0                 4 (18)          3 (8)               1 (13)
  Myalgia                          0                 2 (9)           8 (22)              2 (25)
  Emesis                           0                 0               1 (3)               0
  Diarrhea                         0                 0               6 (17)              0
  Comorbidities                    0                 6 (27)          8 (22)              4 (50)
   Hypertension                    0                 3 (14)          3 (8)               4 (50)
   Diabetes                        0                 3 (14)          1 (3)               0
   Cardiocerebrovascular disease   0                 0               0                   2 (25)
   Chronic lung disease            0                 0               1 (3)               1 (13)
   Chronic kidney disease          0                 0               1 (3)               0
   Chronic liver disease           0                 0               0                   1 (13)
   Other                           0                 2 (9)           4 (11)              0

Data are No. (%) except where indicated.

Abbreviation: NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

![Serum cytokine and chemokine levels of SARS-CoV-2--infected symptomatic (mild, moderate, and severe) patients and healthy controls. Data are expressed as median with 25th and 75th percentiles. \**P \<* .05, \*\**P \<* .01. Abbreviations: CSF, colony-stimulating factor; FGF, fibroblast growth factor; GRO-α, growth related oncogene-α; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; IP-10, IFN-γ inducible protein-10; MCP, monocyte chemoattractant protein; MIG, monokine induced by interferon-γ; MIP, macrophage-inflammatory protein; PDGF, platelet-derived growth factor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis inducing ligand; VEGF, vascular endothelial growth factor.](jiaa363f0001){#F1}

Then we analyzed the cytokine levels in symptomatic cases with the time since onset of symptom, and we found that most of the cytokines whose levels were associated with the severity of COVID-19 peaked at 6 to approximately 8 days (acute phase of disease) after onset ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). However, most of the other cytokines, except IL-1ra and MIF, did not have obvious peak time ([Supplementary Figure 1B](#sup1){ref-type="supplementary-material"}).

Comparison of Cytokine Levels between Male and Female COVID-19 Patients {#s9}
-----------------------------------------------------------------------

As it has been reported that COVID-19 is more likely to occur in men \[[@CIT0007], [@CIT0019]\], we investigate the effect of sex on the serum levels of cytokines and chemokines. The characteristics of SARS-CoV-2--infected male and female symptomatic patients are shown in [Table 3](#T3){ref-type="table"}. The male SARS-CoV-2--infected patients had higher serum concentrations of IL-1β, IL-2, IL-2Rα, IL-3, IL-4, IL-7, IL-8, IL-12 (p40), GM-CSF, IFN-α2, IFN-γ, basic FGF, NGF-β, HGF, LIF, VEGF, MCP-3, and MIP-1α than the female patients ([Figure 2](#F2){ref-type="fig"} and [Supplementary Table 2](#sup2){ref-type="supplementary-material"}).

###### 

Characteristics of SARS-CoV-2--Infected Male and Female Symptomatic Patients

  Characteristic                  Male (n = 37)   Female (n = 29)
  ------------------------------- --------------- -----------------
  Age, y, mean ± SD               41.78 ± 13.33   45.10 ± 16.46
  Time from onset, d, mean ± SD   4.76 ± 4.20     3.97 ± 2.21
  Disease severity                                
   Mild, No. (%)                  13 (35)         9 (31)
   Moderate, No. (%)              19 (51)         17 (59)
   Severe, No. (%)                5 (14)          3 (10)
  Deaths, No. (%)                 0               0

![Serum cytokine and chemokine levels in SARS-CoV-2--infected symptomatic male and female patients. Data are expressed as median with 25th and 75th percentiles. \**P \<* .05, \*\**P \<* .01. Abbreviations: CSF, colony-stimulating factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; LIF, leukemia inhibitory factor; MCP, monocyte chemoattractant protein; MIP, macrophage-inflammatory protein; NGF-β, nerve growth factor-β; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VEGF, vascular endothelial growth factor.](jiaa363f0002){#F2}

Viral Loads Associated with Cytokine and Chemokine Concentrations {#s10}
-----------------------------------------------------------------

To explore the correlations between serum cytokine and chemokine levels and the viral load in SARS-CoV-2--infected patients, Spearman correlation analyses were performed. All the Spearman rank correlation coefficients are showed in a heatmap ([Figure 3A](#F3){ref-type="fig"}). Statistical analysis demonstrated that the levels of MCP-1 (*r* = 0.333, *P*\< .01), G-CSF (*r* = 0.245, *P*\< .05), and VEGF (*r* = 0.300, *P*\< .05) were weakly and positively correlated with the viral load ([Figure 3B](#F3){ref-type="fig"}).

![Correlations between serum cytokine and chemokine levels and viral load in SARS-CoV-2--infected symptomatic patients. *A*, Heatmap showing the Spearman rank correlation coefficients between the levels of serum cytokines and the viral loads. The magnitude of correlation coefficients is shown on a color scale of red (strong) to black (intermediate) to green (weak) signal. *B*, Correlations between MCP-1, G-CSF, and VEGF levels and viral load. Abbreviations: CTACK, cutaneous T cell-attracting chemokine; FGF, fibroblast growth factor; G-CSF, granulocyte-colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor, GRO-α, growth related oncogene α; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; IP-10, IFN-γ inducible protein-10; LIF, leukemia inhibitory factor; MCP-1, monocyte chemoattractant protein-1; MIF, migration inhibitory factor; MIG, monokine induced by interferon-γ; MIP, macrophage-inflammatory protein; NGF-β, nerve growth factor-β; PDGF, platelet-derived growth factor; *r*, correlation coefficient; RANTES, regulated upon activation normal T cell expressed and secreted; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCF, stem cell factor; SCGF-β, stem cell growth factor-β; SDF-1α, stromal cell-derived factor-1α; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; VEGF, vascular endothelial growth factor.](jiaa363f0003){#F3}

DISCUSSION {#s11}
==========

The SARS-CoV-2 epidemic has affecting 189 countries worldwide and has been declared a public health emergency of international concern by the World Health Organization. Cytokine-mediated inflammatory responses have been associated with pulmonary inflammation and acute lung injury in SARS \[[@CIT0014], [@CIT0015]\], MERS-CoV \[[@CIT0012]\], and in recently SARS-CoV-2 \[[@CIT0008], [@CIT0016]\] infection. In this study, we detected the serum levels of 48 cytokines and chemokines in a cohort of 74 patients including asymptomatic, mild, moderate, and severe cases with laboratory-confirmed COVID-19 in Jiangsu, China. Additionally, the relationship between sex, viral load, and serum cytokine and chemokine levels were explored in COVID-19 patients.

No previous studies had evaluated the serum cytokine and chemokine profiles among the asymptomatic, mild, and convalescent cases. Asymptomatic SARS-CoV-2--infected patients who had no symptoms but could still be contagious were identified \[[@CIT0006], [@CIT0020]\]. It is worth noting that asymptomatic and mild cases represent covert SARS-CoV-2 infections that could be seeding new outbreaks and should receive adequate attentions. Here, we found that circulating concentrations of 27 cytokines or chemokines (IL-1β, IL-1ra, IL-2, IL-2Rα, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-15, IL-17, IL-18, G-CSF, M-CSF, IFN-α2, IFN-γ, TNF-α, TRAIL, basic FGF, HGF, PDGF-BB, VEGF, GRO-α, IP-10, MCP-1, and MIG) in symptomatic COVID-19 groups and 3 (IP-10, IL-10, and IL-7) in asymptomatic cases were increased compared to the healthy controls. These results indicated that IP-10, IL-10, and IL-7 may help to identify asymptomatic infections among suspected cases and close contacts. Also, we found that these 3 cytokines were of significant diagnostic value as analyzed by receiver operating characteristic curve (data not shown). The proinflammatory cytokines IL-1ra, IL-1β, IL-6, and chemokine IP-10 were significantly lower in asymptomatic cases than in symptomatic patients, suggesting these factors may be predictors of clinical symptoms. Also, in COVID-19 convalescent individuals, the serum cytokine and chemokine concentrations declined to normal levels. These results demonstrated that proinflammatory cytokines and chemokines production induced by SARS-CoV-2 were observed not only in symptomatic patients but also in the cases without any clinical symptoms, and returned to normal after recovery. These findings indicate that cytokines and chemokines may serve as "messengers" of SARS-CoV-2 infection and contribute to our understanding of the pathogenesis and outcomes throughout all stages of COVID-19.

We then examined these cytokine and chemokine levels in symptomatic patients with different disease severity. The symptomatic cases were categorized into 3 clinical groups, mild cases with slight upper respiratory tract symptoms and no radiological changes, moderate cases with pneumonia and radiological abnormalities, and severe cases with respiratory failure and in some cases death \[[@CIT0017]\]. Severe COVID-19 patients had higher serum levels of IL-6, IL-7, IL-10, G-CSF, M-CSF, IP-10, MCP-1, MCP-3, MIG, and MIP-1α compared with mild cases, and higher levels of MCP-3, MIG, and MIP-1α compared with moderate cases. Moreover, the moderate COVID-19 patients had higher serum concentrations of IL-18, IP-10, and M-CSF than mild cases. Our results suggested that, in addition to IL-6, IL-7, IL-10, G-CSF, IP-10, MCP-1, and MIP-1α which have been previously reported to be associate with the severity of COVID-19 \[[@CIT0008], [@CIT0016]\], IL-18, MCP-3, M-CSF, and MIG might also be predictors of COVID-19 severity. These cytokines and chemokines associated with the severity of COVID-19 were mainly interleukins, chemokines, and colony stimulating factors.

As severe COVID-19 is more likely to occur in men \[[@CIT0007], [@CIT0019]\], we evaluated the serum cytokine and chemokine levels in female and male patients. Our results identified that SARS-CoV-2--infected male patients had significantly higher serum concentrations of IL-1β, IL-2, IL-2Rα, IL-3, IL-4, IL-7, IL-8, IL-12 (p40), GM-CSF, IFN-α2, IFN-γ, basic FGF, NGF-β, HGF, LIF, VEGF, MCP-3, and MIP-1α than female patients. These overproduced cytokine and chemokine profiles in male patients may function to clear pathogens but may also mediate destructive tissue inflammation, which may be interpreted as a reason why male COVID-19 patients are more likely to progress to severe disease. In addition, we found the serum levels of MCP-1, G-CSF, and VEGF were weakly and positively correlated with the viral titers.

The following limitations should be considered in interpretation of our findings. First, the number of subjects was limited due to the difficulty in obtaining samples from asymptomatic and convalescent cases. Second, the virus Ct values may be influenced by the low positive rate of SARS-CoV-2 RNA detection in serum and lack of quantitative viral RNA detection. Therefore, further research is needed to establish the exact involvement of viral and patient factors to verify these immunological responses. Nevertheless, this study demonstrated the circulating cytokine and chemokine profiles present at all stages of the progress of COVID-19.

In this study, we observed that SARS-CoV-2 infection was a potent inducer of proinflammatory cytokines and chemokines, which may be involved in defense against viral infections but may also mediate destructive lung injury. The abnormally elevated IP-10, IL-10, and IL-7 levels in asymptomatic cases may help to identify covert SARS-CoV-2 infections, which would be helpful to control new outbreaks. As disease progresses, an overwhelming induction of IL-6, IL-7, IL-10, IL-18, G-CSF, M-CSF, IP-10, MCP-1, MCP-3, MIG, and MIP-1α was found to be associated with the severity of COVID-19. The circulating cytokine and chemokine profiles returned to normal after recovery. Moreover, a set of cytokine and chemokine profiles were significantly higher in SARS-CoV-2--infected male than female patients. We believe that the cytokine and chemokine response pattern in different stage of the progress of COVID-19 could serve as biomarkers to evaluate the disease severity and outcome of COVID-19 patients. Furthermore, immunomodulatory treatment to regulate the cytokine responses accompanied by antiviral treatment could be an effective therapeutic strategy for SARS-CoV-2 infection.
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